Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer.

Using nonenrichment-based, potentially more sensitive Epic Sciences circulating tumor cell (CTC) platform, we sought to detect and characterize CTCs in untreated, high-risk localized prostate cancer and to evaluate their clinical implication. Between 2012 and 2015, blood samples were prospectively collected from patients with National Comprehensive Cancer Network high-risk localized prostate cancer undergoing either radiotherapy (XRT) plus androgen deprivation therapy or radical prostatectomy (RP) with curative intent. Samples were analyzed with the Epic Sciences platform with 4 A diversity of CTC subtypes, including CK-positive, CK-negative, AR-positive, and CTC clusters, were observed in 73.3% (33 of 45) of patients with evaluable data. The median follow-up was 14.2 months (range, 0.5 to 43.7 months). BCR occurred more frequently in the RP group than XRT (15 of 26 CTCs can be identified in most patients with high-risk localized prostate cancer before definitive therapy using the Epic Sciences platform. If confirmed in a larger cohort with longer follow-up, phenotypic and genomic characterization of CTCs pretherapy may provide an additional means of risk stratifying patients with newly diagnosed high-risk disease and potentially help identify patients who could require multimodal therapy.

Déclaration de conflit d'intérêts

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Ganesh S. Palapattu Stock and Other Ownership Interests: NantKwest Consulting or Advisory Role: Janssen Scientific Affairs Research Funding: Minomic Patents, Royalties, Other Intellectual Property: implantable nanotechnology for long-term testosterone delivery functionalized fiducial marker for drug delivery Brent K. Hollenbeck Other Relationship: Elsevier Joseph D. Schonhoft Employment: Epic Sciences Stock and Other Ownership Interests: Epic Sciences Ryon Graf Employment: Epic Sciences Research Funding: Epic Sciences Travel, Accommodations, Expenses: Epic Sciences Jessica Louw Employment: Epic Sciences, Epic Sciences (I), NAVICAN Genomics Stock and Other Ownership Interests: NAVICAN Genomics Travel, Accommodations, Expenses: NAVICAN Genomics Adam Jendrisak Employment: Epic Sciences Stock and Other Ownership Interests: Epic Sciences Research Funding: Epic Sciences Lyndsey Dugan Employment: NAVICAN Genomics, Human Longevity Stock and Other Ownership Interests: NAVICAN Genomics Consulting or Advisory Role: Human Longevity (Inst), ChromaCode Yipeng Wang Employment: Epic Sciences Stock and Other Ownership Interests: Epic Sciences Scott A. Tomlins Employment: Strata Oncology Leadership: Strata Oncology Stock and Other Ownership Interests: Strata Oncology Consulting or Advisory Role: AbbVie, Janssen, Astellas Medivation, Strata Oncology, Sanofi, Almac Diagnostics Research Funding: Astellas Medivation (Inst), GenomeDx (Inst) Patents, Royalties, Other Intellectual Property: I am a coauthor on a patent issued to the University of Michigan on ETS gene fusions in prostate cancer. The diagnostic field of use has been licensed to Hologic/Gen-Probe, who has sublicensed some rights to Ventana Medical Systems/Roche. Travel, Accommodations, Expenses: Strata Oncology Ryan Dittamore Employment: Epic Sciences Leadership: Epic Sciences Stock and Other Ownership Interests: Epic Sciences Patents, Royalties, Other Intellectual Property: Patents pending Felix Y. Feng Leadership: PFS Genomics Stock and Other Ownership Interests: PFS Genomics Consulting or Advisory Role: Dendreon, EMD Serono, Janssen Oncology, Ferring Pharmaceuticals, Sanofi, Bayer, Blue Earth Diagnostics, Celgene, Medivation/Astellas Research Funding: Zenith Epigenetics Patents, Royalties, Other Intellectual Property: I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst) Todd M. Morgan Consulting or Advisory Role: Myriad Genetics, TerumoBCT Research Funding: Myriad Genetics (Inst), MDxHealth (Inst), GenomeDx (Inst) No other potential conflicts of interest were reported.